Osimertinib - Latest Advances

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775.

Journal: bioRxiv : the preprint server for biology

Published: January 23, 2026

Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation.

Journal: Journal of medicinal chemistry

Published: January 23, 2026

A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine.

Journal: Journal of medicinal chemistry

Published: January 15, 2026

Osimertinib's Proton-Catalyzed, Pseudoconcerted EGFR Inhibition Guides Next-Generation Inhibitor Design.

Journal: Journal of chemical information and modeling

Published: January 02, 2026

Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.

Journal: Thoracic research and practice

Published: December 29, 2025

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Journal: Journal of medicinal chemistry

Published: December 23, 2025

A Dichloropropionamide-Substituted Diaminopyrimidine EGFR-TKI Overcomes Osimertinib Resistance in NSCLC via Dual Anchoring at Ser797 and Met793.

Journal: Journal of medicinal chemistry

Published: December 22, 2025

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Journal: The Journal of international medical research

Published: December 16, 2025

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Journal: American journal of clinical oncology

Published: December 15, 2025

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

Journal: Drug discoveries & therapeutics

Published: December 10, 2025

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes.

Journal: JCO oncology practice

Published: December 09, 2025

Filters

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775.

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775.

Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation.

Tumor-Targeted Delivery of an EGFR Inhibitor Prodrug via Site-Specific Albumin Conjugation.

A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine.

A New Class of Multitargeting PtIV Anticancer Agents: Prodrugs That Release PtII Drugs and Bioactive Moieties Tethered to PtIV via a Tertiary Amine.

Osimertinib's Proton-Catalyzed, Pseudoconcerted EGFR Inhibition Guides Next-Generation Inhibitor Design.

Osimertinib's Proton-Catalyzed, Pseudoconcerted EGFR Inhibition Guides Next-Generation Inhibitor Design.

Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.

Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

A Dichloropropionamide-Substituted Diaminopyrimidine EGFR-TKI Overcomes Osimertinib Resistance in NSCLC via Dual Anchoring at Ser797 and Met793.

A Dichloropropionamide-Substituted Diaminopyrimidine EGFR-TKI Overcomes Osimertinib Resistance in NSCLC via Dual Anchoring at Ser797 and Met793.

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation.

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes.

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes.